Islet cell antibodies and glutamic acid decarboxylase antibodies in patients with insulin-dependent diabetes mellitus undergoing kidney and islet-after-kidney transplantation

Transplantation

Volumn 62, Issue 3, 1996, Pages 424-426

  Jaeger, Clemens ^a   Hering, Bernhard J ^a   Dyrberg, Thomas ^b   Federlin, Konrad ^a   Bretzel, Reinhard G ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME ANTIBODY; GLUTAMATE DECARBOXYLASE; PANCREAS ISLET CELL ANTIBODY;

ADULT; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; AUTOIMMUNITY; CLINICAL ARTICLE; COMPLICATION; CONTROLLED STUDY; ETIOLOGY; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY TRANSPLANTATION; MALE; PANCREAS ISLET TRANSPLANTATION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL;

EID: 0029819877     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199608150-00023     Document Type: Article

References (11)

1. Naji A, Silvers WK, Bellgrau D, Barker CF. Spontaneous diabetes in rats: destruction of islets is prevented by immunologic tolerance. Science 1981; 213: 1390.
2. Sibley RK, Sutherland DER, Goetz F, Michael AF. Recurrent diabetes mellitus in the pancreas iso- and allograft: a light and electron microscopic and immunohistochemical analysis of four cases. Lab Invest 1985; 53: 132.
3. Bartlett ST, Hadley GA, Dirden B, et al. Composite kidney-islet transplantation prevents recurrent autoimmune beta-cell destruction. Surgery 1993; 114: 211.
4. Bartlett ST, Chin T, Dirden B, Quereshi A, Hadley G. Inclusion of peripancreatic lymph node cells prevents recurrent autoimmune destruction of islet transplants: evidence of donor chimerism. Surgery 1995; 118: 392.
5. Hering BJ, Browatzki CC, Schultz A, Bretzel RG, Federlin K. Clinical islet transplantation registry report: accomplishments in the past and future research needs. Cell Transplant 1993; 2: 269.
6. Petersen JC, Hejnaes KR, Moody A, et al. Detection of GAD 65 antibodies in diabetes and other autoimmune diseases using a simple radioligand assay. Diabetes 1994; 43: 459.
7. Mandrup-Poulson T, Nerup J, Stiller CR, et al. Disappearance and reappearance of islet cell cytoplasmatic antibodies in cyclosporin-treated insulin-dependent diabetics. Lancet 1985; 2: 599.
8. Mandrup-Poulson T, Molvig J, Andersen HU, et al. Lack of predictive value of islet cell antibodies, insulin antibodies and HLA-DR phenotype for remission in cyclosporin-treated IDDM patients. Diabetes 1990; 39: 204.
9. Castano L, Boitard C, Bougneres PF. Cyclosporine A suppresses insulin autoantibodies and heterologous insulin antibodies in type I diabetic children. Diabetes 1988; 37: 1049.
10. Petersen JS, Dyrberg T, Karlsen AE, et al. Glutamic acid decarboxylase (GAD 65) autoantibodies in prediction of β-cell function and remission in recent-onset IDDM after cyclosporin treatment. Diabetes 1994; 43: 1291.
11. Bretzel RG, Browatzki CC, Schultz A, et al. Clinical islet transplantation - report of the islet transplant registry and the Giessen center experience. Diab Stoffw 1993; 2: 378.